---
schema_version: "secwatch.filing_event.v1"
accession: "0001576280-24-000260"
form_type: "8-K"
ticker: "GH"
cik: "0001576280"
company_name: "Guardant Health, Inc."
filed_at: "2024-11-06T23:59:59+00:00"
generated_at: "2026-05-30T04:32:56.661944+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Guardant Health Q3 revenue $191.5M (+34% YoY); raises FY 2024 revenue guidance to $720-725M

## Summary
- Revenue $191.5M (+34% YoY); GAAP net loss $107.8M ($0.88/shr), Non-GAAP net loss $55.0M ($0.45/shr).
- Clinical test volume 53,100 (+21%), biopharma 10,500 (+40%); Guardant360 ASP >$3,000.
- Full-year 2024 revenue guidance raised to $720-725M (prior $690-700M), growth 28-29%.
- Free cash flow guidance improved to $(265)-$(275)M, improvement of $70-80M vs 2023.
- Shield IVD launched; received Medicare pricing of $920; CMS removed cost-sharing for follow-on colonoscopy.

## SEC filing metadata
- accession: 0001576280-24-000260
- form_type: 8-K
- ticker: GH
- cik: 0001576280
- company_name: Guardant Health, Inc.
- filed_at: 2024-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1576280/000157628024000260/0001576280-24-000260-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1576280/000157628024000260/gh-20241106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001576280-24-000260
- JSON: https://secwatch.observer/filing/0001576280-24-000260.json
- Plain text: https://secwatch.observer/filing/0001576280-24-000260.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.